Sven D. Koch

3.3k total citations · 1 hit paper
42 papers, 2.0k citations indexed

About

Sven D. Koch is a scholar working on Immunology, Molecular Biology and Epidemiology. According to data from OpenAlex, Sven D. Koch has authored 42 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Immunology, 11 papers in Molecular Biology and 10 papers in Epidemiology. Recurrent topics in Sven D. Koch's work include Immunotherapy and Immune Responses (14 papers), T-cell and B-cell Immunology (12 papers) and Immune Cell Function and Interaction (11 papers). Sven D. Koch is often cited by papers focused on Immunotherapy and Immune Responses (14 papers), T-cell and B-cell Immunology (12 papers) and Immune Cell Function and Interaction (11 papers). Sven D. Koch collaborates with scholars based in Germany, Netherlands and Switzerland. Sven D. Koch's co-authors include Graham Pawelec, Anis Larbi, Dennis Özcelik, Mariola Fotin‐Mleczek, Elissaveta Naumova, Evelyna Derhovanessian, Rafael Solana, Ulrike Gnad-Vogt, Anders Wikby and Cécile Gouttefangeas and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Sven D. Koch

40 papers receiving 1.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial

2017 373 citations Ulrike Gnad-Vogt, Henoch S. Hong et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sven D. Koch Germany	19	1.1k	649	473	394	313	42	2.0k
Anna Cerny United States	25	1.0k 0.9×	518 0.8×	606 1.3×	304 0.8×	179 0.6×	29	1.9k
K. Kai McKinstry United States	20	1.6k 1.5×	286 0.4×	767 1.6×	399 1.0×	261 0.8×	22	2.3k
Jacob E. Kohlmeier United States	34	3.2k 2.9×	571 0.9×	1.1k 2.3×	539 1.4×	491 1.6×	73	4.1k
Norina Tang United States	14	598 0.5×	945 1.5×	730 1.5×	277 0.7×	105 0.3×	18	2.2k
Francisco A. Bonilla United States	24	1.7k 1.6×	491 0.8×	426 0.9×	189 0.5×	242 0.8×	60	2.5k
Matthias Tenbusch Germany	28	886 0.8×	491 0.8×	452 1.0×	422 1.1×	115 0.4×	91	2.1k
Olga L. Rojas Canada	18	739 0.7×	306 0.5×	144 0.3×	338 0.9×	160 0.5×	36	1.5k
Tomer Granot United States	14	1.3k 1.2×	271 0.4×	228 0.5×	156 0.4×	343 1.1×	15	1.7k
Cherie Ng United States	14	896 0.8×	320 0.5×	307 0.6×	369 0.9×	240 0.8×	31	1.6k
Ahmed N. Hegazy Germany	22	2.7k 2.5×	610 0.9×	291 0.6×	329 0.8×	380 1.2×	44	3.5k

Countries citing papers authored by Sven D. Koch

Since Specialization

Citations

This map shows the geographic impact of Sven D. Koch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sven D. Koch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sven D. Koch more than expected).

Fields of papers citing papers by Sven D. Koch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sven D. Koch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sven D. Koch. The network helps show where Sven D. Koch may publish in the future.

Co-authorship network of co-authors of Sven D. Koch

This figure shows the co-authorship network connecting the top 25 collaborators of Sven D. Koch. A scholar is included among the top collaborators of Sven D. Koch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sven D. Koch. Sven D. Koch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Frères, Pierre, Martin Glas, Martin J. van den Bent, et al.. (2024). 440O First in human study of the mRNA-based cancer vaccine CVGBM in patients (pts) with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma (GBM): First results from the dose escalation phase. Annals of Oncology. 35. S406–S406. 2 indexed citations

Tabatabai, Ghazaleh, Louisa von Baumgarten, Martin J. van den Bent, et al.. (2024). Phase 1 dose-finding study to evaluate safety and tolerability of CVGBM in patients with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma.. Journal of Clinical Oncology. 42(16_suppl). TPS2095–TPS2095. 3 indexed citations

Wolz, Olaf‐Oliver, Dominik Vahrenhorst, Gianluca Quintini, et al.. (2024). Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity. Vaccines. 12(4). 388–388. 1 indexed citations

Wolz, Olaf‐Oliver, et al.. (2022). A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant. Vaccines. 10(4). 508–508. 9 indexed citations

Stenzl, Arnulf, Isabel Syndikus, Tomasz Sarosiek, et al.. (2017). Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 28. v408–v409. 32 indexed citations

Remmerswaal, Ester B. M., Paul L. Klarenbeek, Nuno L. Alves, et al.. (2014). Clonal Evolution of CD8⁺T Cell Responses against Latent Viruses: Relationship among Phenotype, Localization, and Function. Journal of Virology. 89(1). 568–580. 25 indexed citations

Kowalczyk, Aleksandra, Edith Jasny, Birgit Scheel, et al.. (2014). Self-adjuvanted RNActive® vaccine induces local immune responses at the injection site leading to potent adaptive immunity in mice and humans. Journal for ImmunoTherapy of Cancer. 2(S3). 1 indexed citations

Koch, Sven D., Henoch S. Hong, Susan Feyerabend, et al.. (2014). A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive®-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part. Journal for ImmunoTherapy of Cancer. 2(Suppl 3). P85–P85. 5 indexed citations

Kallen, Karl‐Josef, Regina Heidenreich, Margit Schnee, et al.. (2013). A novel, disruptive vaccination technology. Human Vaccines & Immunotherapeutics. 9(10). 2263–2276. 184 indexed citations

10.

Berg, Pablo J. E. J. van de, Sandro L. Yong, Sven D. Koch, et al.. (2011). Characteristics of alloreactive T cells measured before renal transplantation. Clinical & Experimental Immunology. 168(2). 241–250. 7 indexed citations

11.

Minnee, Robert C., Sven D. Koch, Aeilko H. Zwinderman, et al.. (2010). Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses. Kidney International. 78(9). 934–940. 57 indexed citations

12.

Attig, Sebastian, Jörg Hennenlotter, Graham Pawelec, et al.. (2009). Simultaneous Infiltration of Polyfunctional Effector and Suppressor T Cells into Renal Cell Carcinomas. Cancer Research. 69(21). 8412–8419. 76 indexed citations

13.

Koch, Sven D., et al.. (2008). Alloantigen-induced regulatory CD8+CD103+ T cells. Human Immunology. 69(11). 737–744. 35 indexed citations

14.

Koch, Sven D., Anis Larbi, Evelyna Derhovanessian, et al.. (2008). Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. Immunity & Ageing. 5(1). 6–6. 274 indexed citations

15.

Derhovanessian, Evelyna, Cécile Gouttefangeas, Sven D. Koch, & Graham Pawelec. (2008). Monitoring T Cell Responses to Cancer Immunotherapy: Can We Now Identify Biomarkers Predicting Patients Who will be Responders. Current Cancer Therapy Reviews. 4(2). 111–119. 1 indexed citations

16.

Schuh, Günther, et al.. (2007). Objektorientierte Fabrikplanung : Teil 1: Modellierung modularer Produktionsstrukturen. RWTH Publications (RWTH Aachen). 1 indexed citations

17.

Pawelec, Graham, Sven D. Koch, Cécile Gouttefangeas, & Anders Wikby. (2006). Immunorejuvenation in the Elderly. Rejuvenation Research. 9(1). 111–116. 27 indexed citations

18.

Pawelec, Graham, Sven D. Koch, Claudio Franceschi, & Anders Wikby. (2006). Human Immunosenescence. Annals of the New York Academy of Sciences. 1067(1). 56–65. 70 indexed citations

19.

Walter, Steffen, Gilles Bioley, Hans‐Jörg Bühring, et al.. (2005). High frequencies of functionally impaired cytokeratin 18‐specific CD8⁺ T cells in healthy HLA‐A2⁺ donors. European Journal of Immunology. 35(10). 2876–2885. 22 indexed citations

20.

Pawelec, Graham, et al.. (2005). Immunosenescence, suppression and tumour progression. Cancer Immunology Immunotherapy. 55(8). 981–986. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact